Reality of Rare Diseases: A Unique Perspective About Rare Diseases
The Evolved Gene Therapy for Hemophilia
medtech-news-for-boston-scientific-bd-roche-linus-helioliver
Boston Scientific’s MODULAR CRM...

Boston Scientific initiates trial to evaluate industry's first Modular CRM System  On December 02, 202...

pharma-news-for-aslan-iqvia-reata-recordati-eusa
Aslan Pharma – IQVIA collaborat...

Aslan Pharmaceuticals enters into a strategic collaboration with IQVIA   ASLAN Pharmaceuticals an...

pharma-news-for-bluebird-bio-fda-twist-bioscience-sosei-heptares
Bluebird bio may get gene therapy app...

Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved i...

Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these facto...


Fda-Approved-Top-Drugs-Launched-in-2021
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of...

Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceut...


von-willebrand-disease-vwd-market
von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improperly. Blood contains numerous proteins that aid in blood clotting when necessary. Von Willebrand factor is on...


recent-pharma-news-for-biogen-phathom-vertex-natera
Biogen’s ALS drug Tofersen (BIIB067); Phathom’s erosive esophagitis drug trial; Verte...

Biogen’s tofersen fails to meet the primary goal in the Phase III ALS trial Biogen has announced that its investigational antisense drug, tofersen (BIIB067), flunked to meet the primary goal of...


pharma-biotech-news-updates-for-pfizer-kytopen-eli-lilly-vensana-reify-health
Pfizer tightens DMD trial criteria over safety concerns; Kytopen raises $30M; Eli Lilly taps Reif...

Pfizer tightens DMD patient criteria after serious adverse events in phase 3 gene therapy trial Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to partake in phase...


myasthenia-gravis-treatment-market-growth-size-therapies-forecast-and-key-companies
Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It occurs when the communication between nerve cells and muscles is disrupted. This impairment prevents critical...


Editor's Pick
22 Healthcare Trends & Innovations to Watch in 2022 and Beyond

With the advent of new-age healthcare industry trends that are evident as of now, there...

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did...

Analyzing the Key Trends Driving the Biosimilar Market Growth

The Biosimilars market is growing at a breakneck pace. The biosimilar market provides a...

CAR-T Cell Therapy aka Miraculous Technology: Mapping the Market, Approved Th...

Chimeric antigen receptor T-cell (CAR T) therapies are shown to have transformative pot...

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Finding...

There has been limited progress in the approval of novel agents in MDS. It has been a l...